Reviewer's report

Title: Primary PEComa of the Bladder Treated with Primary Excision and Adjuvant Interferon-Alpha Immunotherapy: A Case Report

Version: 1 Date: 14 May 2006

Reviewer: Conrad Fernandez

Reviewer's report:

General
Well written and concise report.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

1. Clarify the discrepancy between the 3 cm mass seen at cystoscopy and the pathological size of the specimen (did the Ct suggest this size?)
2. The report would benefit from a more detailed description of the invasiveness of this lesion - did it invade bowel on pathology, were there lymph nodes sampled, were there positive margins?
3. The report would benefit from a description of evidence that supports use of interferon in other vascular tumors given its expected side effect profile and cost? How was it tolerated in this patient?
4. The report would benefit from including a statement recognizing that a limitation of this case report is that there was no residual tumor. Unclear whether or not the interferon had any impact on lack of recurrence, esp since the tumor's behaviour is difficult to predict based on size, histology, invasiveness (except if metastatic). A balanced comment regarding weighing risks of interferon vs. benefits in a situation where any tumor activity is unproven should be added.

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
Comma missing on page 5 between "(CCSSP)" and "metastatic"

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:
I declare that I have no competing interests.